TABLE 2

Pharmacokinetic parameters for repaglinide and inhibition parameters

Parameters	Units	Values	Sources
Bioavailability		0.625	Hatorp, 2002
CL_tot (plasma)	l/h	32.6	Hatorp, 2002
CL_tot (blood)	l/h	52.6	CL_tot (plasma) / R_b
f_e		0.001	van Heiningen et al., 1999
CL_h (blood)	l/h	52.6	Assuming CL_r = 0
F_h		0.40	1-CL_h/Q_h
F_aF_g		1	Bioavailability > F_h
f_p		0.015	Hatorp, 2002
f_b		0.025	f_p / R_b
R_b		0.6	van Heiningen et al., 1999
Dose	μg	250	Niemi et al., 2003a
k_a	h⁻¹	4.51 ± 1.87	^*
Lag	h	1.20 ± 0.06	^*
V_b	l	8.38 ± 9.02	^*
f_h·CL_int	l/h	5.63 ± 4.88	^*
f_b·PS_inf	l/h	192 ± 127	^*
f_h·PS_eff	l/h	15.4	Yabe et al., 2011; Ménochet et al., 2012; Jones et al., 2012
k₁₂	h⁻¹	2.62 ± 3.60	^*
k₂₁	h⁻¹	1.23 ± 0.30	^*
fm_2C8		0.801 ± 0.049	^*
K_i,3A4,icz	μg/l	0.0477 ± 0.0365	^*
K_i,app,2C8	μM	20	Ogilvie et al., 2006
k_inact,2C8	h⁻¹	12.6	Ogilvie et al., 2006
k_deg,2C8	h⁻¹	0.03013	Yang et al., 2008
K_i,1B1,gem	μg/l	3,560 ± 2,530	^*
K_i,1B1,glu/K_i,1B1,gem		0.385	Shitara et al., 2004; Nakagomi-Hagihara et al., 2007